Home › Funds › Baugh & Associates, LLC › ABT

Baugh & Associates, LLC position in ABT

ABBOTT LABORATORIES · Health Care

Baugh & Associates, LLC reported holding 56,570 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$4.8M, representing 2.16% of its reported portfolio and ranking #25 among its reported holdings. Baugh & Associates, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)56.57K sh
Reported value held$4.76M
Portfolio Weight2.16%
First reportedQ3 2023
Last changeAdd
Updated2026-10-16

Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR

How Baugh & Associates, LLC's ABT position evolved

Baugh & Associates, LLC first disclosed a stake in ABT in Q3 2023 at 55,341 shares (US$5.4M). The position peaked in Q1 2025 at 56,725 shares, worth US$7.2M. Across 13 filings, Baugh & Associates, LLC increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 56,570 shares valued at US$4.8M — an increase of 6,436 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 55.34K $5.36M New
Q4 2023 54.68K $6.02M Reduce
Q1 2024 54.63K $6.21M Hold
Q2 2024 52.19K $5.67M Reduce
Q3 2024 56.92K $6.22M Add
Q4 2024 56.91K $6.16M Hold
Q1 2025 56.73K $7.15M Hold
Q2 2025 53.82K $6.68M Reduce
Q3 2025 52.96K $6.42M Reduce
Q4 2025 51.22K $5.75M Reduce
Q1 2026 58.30K $5.99M Add
Q2 2026 50.13K $4.55M Reduce
Q3 2026 56.57K $4.76M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Baugh & Associates, LLC held ABT?

Baugh & Associates, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Baugh & Associates, LLC's current position in ABT?

As of Q3 2026, Baugh & Associates, LLC holds 56.57K shares of ABT (ABBOTT LABORATORIES), valued at $4.76M, representing 2.16% of its reported portfolio and ranking #25.

Has Baugh & Associates, LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Baugh & Associates, LLC increased its position in ABT. The position peaked in Q1 2025 at 56.73K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.